Athira Pharma logo
Athira Pharma ATHA

Quarterly report 2025-Q3
added 11-06-2025

report update icon

Athira Pharma Balance Sheet 2011-2026 | ATHA

Annual Balance Sheet Athira Pharma

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

-47.2 M -89 M -94.1 M -109 M -60.6 M -503 K -2.6 M - - - - - - -

Long Term Debt

803 K 1.22 M 1.58 M 1.63 M - 1.55 M 722 K - - - - - - -

Long Term Debt Current

414 K 368 K 326 K 288 K 124 K - - - - - - - - -

Total Non Current Liabilities

- - - - 876 K 20.6 M 19.2 M - - - - - - -

Total Current Liabilities

13.1 M 28.8 M 21.4 M 9.29 M 4.4 M - - - - - - - - -

Total Liabilities

13.9 M 30.1 M 23 M 10.9 M 5.28 M 21.9 M 19.8 M - - - - - - -

Retained Earnings

-406 M -309 M -192 M -95.9 M - -21.1 M -15.9 M - - - - - - -

Total Assets

58.8 M 160 M 258 M 332 M 280 M 2.19 M 4.93 M - - - - - - -

Cash and Cash Equivalents

48.4 M 90.6 M 96 M 111 M 60.6 M - - - - - - - - -

Book Value

44.8 M 130 M 235 M 321 M 274 M -19.7 M -14.9 M - - - - - - -

Total Shareholders Equity

44.8 M 130 M 235 M 321 M 274 M -19.7 M - - - - - - - -

All numbers in USD currency

Quarterly Balance Sheet Athira Pharma

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

460 K 578 K 691 K 803 K 912 K 1.02 M 1.12 M 1.22 M 1.31 M 1.41 M 1.5 M 1.58 M 1.67 M 1.75 M 1.55 M 1.63 M 1.71 M 1.78 M 1.7 M 876 K 876 K 876 K 876 K 1.55 M 1.55 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

3.25 M 3.56 M 6.18 M 13.9 M 28.7 M 27.9 M 26.7 M 30.1 M 29.9 M 23.1 M 21.6 M 23 M 11.9 M 11.4 M 11 M 10.9 M 11.1 M 9.42 M 6.2 M 5.28 M 5.28 M 5.28 M 5.28 M 4.86 M 4.86 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

-429 M -422 M -415 M -406 M -391 M -362 M -336 M -309 M -282 M -249 M -219 M -192 M -161 M -141 M -117 M -95.9 M -79.6 M -63.9 M -49.9 M -41 M -41 M -41 M -41 M -21.1 M -21.1 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

30 M 35.5 M 43.5 M 58.8 M 86.2 M 111 M 133 M 160 M 185 M 208 M 233 M 258 M 274 M 292 M 313 M 332 M 347 M 360 M 369 M 280 M 280 M 280 M 280 M 2.19 M 2.19 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

20.9 M 19.9 M 26.4 M 48.4 M 68.9 M 73.8 M 77.8 M 90.6 M 110 M 114 M 105 M 96 M 87 M 95.1 M 118 M 111 M 107 M 132 M 128 M 60.6 M 60.6 M 60.6 M 60.6 M 2.06 M 2.06 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Book Value

26.8 M 32 M 37.3 M 44.8 M 57.6 M 83.3 M 107 M 130 M 155 M 185 M 211 M 235 M 262 M 281 M 302 M 321 M 336 M 351 M 363 M 274 M 274 M 274 M 274 M -2.67 M -2.67 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

26.8 M 32 M 37.3 M 44.8 M 57.6 M 83.3 M 107 M 130 M 155 M 185 M 211 M 235 M 262 M 281 M 302 M 321 M 336 M 351 M 363 M 274 M 274 M 274 M 274 M -19.7 M -19.7 M -17.4 M - -14.9 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Balance Sheet is a fundamental financial report of Athira Pharma, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Alector Alector
ALEC
$ 2.11 -13.17 % $ 217 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Apellis Pharmaceuticals Apellis Pharmaceuticals
APLS
$ 20.52 -2.12 % $ 2.59 B usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Axsome Therapeutics Axsome Therapeutics
AXSM
$ 164.13 0.15 % $ 8.17 B usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Aytu BioScience Aytu BioScience
AYTU
$ 2.49 -3.11 % $ 15.6 M usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
BridgeBio Pharma BridgeBio Pharma
BBIO
$ 64.24 -3.37 % $ 12.3 B usaUSA
BioAtla BioAtla
BCAB
$ 0.18 -26.92 % $ 8.6 M usaUSA
BioCardia BioCardia
BCDA
$ 1.37 6.2 % $ 29 M usaUSA
BioCryst Pharmaceuticals BioCryst Pharmaceuticals
BCRX
$ 8.61 -1.66 % $ 1.78 B usaUSA
Black Diamond Therapeutics Black Diamond Therapeutics
BDTX
$ 2.4 -3.04 % $ 132 M usaUSA
Beam Therapeutics Beam Therapeutics
BEAM
$ 28.29 -0.6 % $ 2.8 B usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Biohaven Pharmaceutical Holding Company Ltd. Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$ 11.47 -0.43 % $ 742 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Biogen Biogen
BIIB
$ 187.68 -2.16 % $ 27.5 B usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
BioVie BioVie
BIVI
$ 1.38 -0.01 % $ 2.04 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
BioLineRx Ltd. BioLineRx Ltd.
BLRX
$ 2.91 2.83 % $ 908 M israelIsrael
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 60.68 -1.7 % $ 11.6 B usaUSA
Bristol-Myers Squibb Company Bristol-Myers Squibb Company
BMY
$ 62.54 0.27 % $ 127 B usaUSA
Benitec Biopharma Benitec Biopharma
BNTC
$ 10.85 -0.5 % $ 447 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 109.85 -0.34 % $ 27.2 B germanyGermany
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
BioXcel Therapeutics BioXcel Therapeutics
BTAI
$ 1.63 -2.69 % $ 4.13 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 8.6 1.9 % $ 1.39 B britainBritain